What is Abivax?
Abivax operates at the intersection of immunology and drug discovery, specializing in the development of novel therapeutics that harness the body's innate immune response. By targeting specific pathways involved in inflammation and viral replication, the company aims to provide transformative treatments for patients suffering from chronic autoimmune disorders and cancer. As a clinical-stage entity, Abivax maintains a rigorous focus on translational research, moving promising candidates through the regulatory pipeline with the goal of establishing a new standard of care in its therapeutic focus areas.
How much funding has Abivax raised?
Abivax has raised a total of $67M across 3 funding rounds:
Debt
$436K
Debt
$17.6M
Other Financing Round
$49M
Debt (2017): $436K with participation from Region Occitanie and Bpifrance
Debt (2020): $17.6M led by Kreos Capital
Other Financing Round (2022): $49M supported by Venrock Healthcare Capital Partners and Tcgx
Key Investors in Abivax
Bpifrance
Founded in 2012, based out of France, Bpifrance finances companies at each stage of their development with credit, guarantees, and equity, supporting innovation and international expansion.
Kreos Capital
Kreos Capital Group Ltd is a London-based firm established in 1998 that specializes in providing growth debt and investment services to high-growth companies.
Tcgx
Tcgx is an investment entity focused on supporting innovative companies within the life sciences and biotechnology sectors.
What's next for Abivax?
Looking ahead, the strategic deployment of the $49M will likely prioritize the advancement of lead clinical assets through late-stage trials. The company's roadmap involves strengthening its intellectual property portfolio and expanding its international research collaborations. Given the current enterprise-level funding trajectory, Abivax is poised to transition from a research-heavy organization to a commercial-ready biotech player, provided it continues to demonstrate efficacy in its ongoing clinical studies. Investors will be closely monitoring the firm's ability to navigate the complex regulatory landscape while maintaining its momentum in immune-modulating drug development.
See full Abivax company page
